<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02538172</url>
  </required_header>
  <id_info>
    <org_study_id>STCS FUP # 052</org_study_id>
    <nct_id>NCT02538172</nct_id>
  </id_info>
  <brief_title>Cell-mediated Immunity for Prevention of CMV Disease</brief_title>
  <official_title>Monitoring of Specific Cytomegalovirus Cell-mediated Immunity (CMV-CMI) for Optimization of Preventive Strategies Against CMV Infection in High-risk Solid-organ Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Lausanne Hospitals</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Lausanne Hospitals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label randomized controlled trial to adapt the duration of antiviral prophylaxis in
      D+/R- patients and in R+ patients receiving ATG according to the result of the T-Track® CMV
      assay. Investigators will include kidney and liver transplant recipients. Patients will be
      randomized during the first month post transplant.

      In the interventional arm, while the patient is on antiviral prophylaxis, CMI will be
      monitored every 4 weeks from the 2nd month after transplant. Measurement of CMV CMI will be
      done in real time by using the T-Track® CMV assay. The continuation of antiviral prophylaxis
      will depend on the result of the assay:

        -  T-Track positive (patient at lower risk): discontinuation of the antiviral drug

        -  T-Track negative (patient at higher risk): continuation of the antiviral drug until the
           maximal duration of prophylaxis (3 to 6 months) The standard arm will receive a standard
           fixed duration of antiviral prophylaxis (3 months for R+ thymoglobulin treated-patients
           and 6 months for D+/R- patients). Measurement of CMV CMI by both T-Track® CMV and the
           Quantiferon-CMV® assays will be done at the same time points of the interventional arm,
           but the result will not be known by the investigators.

      After discontinuation of prophylaxis, patients in both arms will be followed for the
      development of CMV replication at each visit using the local PCR assay and antiviral therapy
      will be administered in case of CMV infection according to local guidelines.

      The co-primary endpoints will be the incidence of CMV disease or antiviral-treated CMV
      replication during the first 12 months post transplant AND the duration of antiviral
      prophylaxis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of CMV infection</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of antiviral prophylaxis</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Graft survival</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of CMV viremia using standardized measure</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Cytomegalovirus Infections</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T-Track® CMV assay Quantiferon-CMV® assays Valganciclovir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>T-Track® CMV assay Quantiferon-CMV® assays Valganciclovir</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>T-Track® CMV assay</intervention_name>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <other_name>Quantiferon-CMV® assays</other_name>
    <other_name>Valganciclovir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years old

          -  Kidney or liver transplantation

          -  Scheduled to receive CMV antiviral prophylaxis:

          -  CMV D+/R- patients

          -  Patients receiving lymphocyte-depleting antibodies (thymoglobulin® or ATG®)

        Exclusion Criteria:

          -  Unable to provide informed consent

          -  Unable or unwilling to comply with study protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oriol Manuel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Lausanne Hospitals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Oriol Manuel, MD</last_name>
    <phone>+41 21 314 30 20</phone>
    <email>oriol.manuel@chuv.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Deolinda Alves</last_name>
    <phone>+41 21 314 10 01</phone>
    <email>deolinda.alves@chuv.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universität Basel</name>
      <address>
        <city>Basel</city>
        <zip>4051</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans Hirsch, MD</last_name>
      <email>hans.hirsch@unibas.ch</email>
    </contact>
    <investigator>
      <last_name>Hans Hirsch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cedric HIrzel, MD</last_name>
      <email>Cedric.Hirzel@insel.ch</email>
    </contact>
    <investigator>
      <last_name>Cedric Hirzel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaires de Genève</name>
      <address>
        <city>Genève</city>
        <zip>1205</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Van Delden, MD</last_name>
      <email>Christian.vanDelden@hcuge.ch</email>
    </contact>
    <investigator>
      <last_name>Christian Van Delden, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St.Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Hoffmann, MD</last_name>
      <email>Matthias.Hoffmann@kssg.ch</email>
    </contact>
    <investigator>
      <last_name>Matthias Hoffmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UniversitätsSpital Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Mueller, MD</last_name>
      <email>Nicolas.Mueller@usz.ch</email>
    </contact>
    <investigator>
      <last_name>Nicolas Mueller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Manuel O, Husain S, Kumar D, Zayas C, Mawhorter S, Levi ME, Kalpoe J, Lisboa L, Ely L, Kaul DR, Schwartz BS, Morris MI, Ison MG, Yen-Lieberman B, Sebastian A, Assi M, Humar A. Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. Clin Infect Dis. 2013 Mar;56(6):817-24. doi: 10.1093/cid/cis993. Epub 2012 Nov 29.</citation>
    <PMID>23196955</PMID>
  </results_reference>
  <results_reference>
    <citation>Manuel O. Clinical Experience with Immune Monitoring for Cytomegalovirus in Solid-Organ Transplant Recipients. Curr Infect Dis Rep. 2013 Sep 29. [Epub ahead of print]</citation>
    <PMID>24078428</PMID>
  </results_reference>
  <results_reference>
    <citation>Humar A, Lebranchu Y, Vincenti F, Blumberg EA, Punch JD, Limaye AP, Abramowicz D, Jardine AG, Voulgari AT, Ives J, Hauser IA, Peeters P. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant. 2010 May;10(5):1228-37. doi: 10.1111/j.1600-6143.2010.03074.x. Epub 2010 Mar 26.</citation>
    <PMID>20353469</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2015</study_first_submitted>
  <study_first_submitted_qc>August 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2015</study_first_posted>
  <last_update_submitted>April 6, 2018</last_update_submitted>
  <last_update_submitted_qc>April 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Lausanne Hospitals</investigator_affiliation>
    <investigator_full_name>Oriol Manuel</investigator_full_name>
    <investigator_title>Privat-Docent (PD)</investigator_title>
  </responsible_party>
  <keyword>Cell-mediated immunity</keyword>
  <keyword>Antiviral prophylaxis</keyword>
  <keyword>Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valganciclovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

